endometrial carcinoma (Cancer)
Information
- Disease name
- endometrial carcinoma
- Disease ID
- DOID:2871
- Description
- "A endometrial cancer that is located_in the tissue lining the uterus." [url:http\://www.cancer.gov/cancertopics/types/endometrial]
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| PTEN | 10 | 87,863,625 | 87,971,930 | 32 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04713618 | Active, not recruiting | Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy | January 30, 2021 | December 31, 2026 | |
| NCT02730923 | Active, not recruiting | Phase 1/Phase 2 | Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA) | April 2016 | December 2024 |
| NCT04634617 | Active, not recruiting | Pelvic Floor Dysfunction and Quality of Life in Uterine Cancer Survivors | January 9, 2020 | April 11, 2025 | |
| NCT02465060 | Active, not recruiting | Phase 2 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | August 17, 2015 | December 31, 2025 |
| NCT01366144 | Active, not recruiting | Phase 1 | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | June 20, 2011 | March 5, 2025 |
| NCT00791635 | Active, not recruiting | Longitudinal Evaluation of Women Undergoing Pelvic Surgery for the Treatment of Gynecologic Cancer | July 11, 2008 | September 30, 2025 | |
| NCT02584478 | Active, not recruiting | Phase 3 | Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | December 2015 | December 2024 |
| NCT03752398 | Active, not recruiting | Phase 1 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) | May 1, 2019 | September 2025 |
| NCT02598219 | Active, not recruiting | Phase 3 | Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence. | November 2015 | October 2027 |
| NCT04257045 | Active, not recruiting | Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives | August 21, 2019 | April 30, 2024 | |
| NCT03917381 | Active, not recruiting | Phase 1/Phase 2 | GEN1046 Safety Trial in Patients With Malignant Solid Tumors | May 14, 2019 | October 2025 |
| NCT03460483 | Active, not recruiting | N/A | Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care | March 30, 2018 | June 30, 2023 |
| NCT05407025 | Active, not recruiting | Targeting Inflammation for Endometrial Cancer Prevention | December 1, 2021 | December 31, 2025 | |
| NCT03671811 | Active, not recruiting | Phase 2 | Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy | January 21, 2019 | November 7, 2024 |
| NCT03745950 | Active, not recruiting | Phase 2 | UTOLA: UTerin OLAparib | February 1, 2019 | December 2024 |
| NCT02807844 | Completed | Phase 1/Phase 2 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | June 29, 2016 | June 4, 2020 |
| NCT02977195 | Completed | Phase 1 | First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targeting Netrin 1 in Patients With Advanced/Metastatic Solid Tumors | January 9, 2017 | June 2022 |
| NCT02983279 | Completed | N/A | Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer | September 20, 2016 | December 29, 2022 |
| NCT03015129 | Completed | Phase 2 | A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer | January 2017 | December 30, 2022 |
| NCT03027479 | Completed | N/A | Skeletal Muscle Energy Metabolism in Women With Weight Loss and Ovarian and/or Endometrial Cancer With Weight Loss | March 1, 2017 | July 16, 2019 |
| NCT03241745 | Completed | Phase 2 | A Study of Nivolumab in Selected Uterine Cancer Patients | August 3, 2017 | April 1, 2024 |
| NCT03367923 | Completed | Phase 2 | Health and Recovery Program in Increasing Physical Activity Level in Stage IA-IIIA Endometrial Cancer Survivors | December 1, 2017 | March 25, 2020 |
| NCT03372720 | Completed | N/A | Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors | May 11, 2018 | April 12, 2022 |
| NCT03517488 | Completed | Phase 1 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | July 10, 2018 | September 6, 2022 |
| NCT00165126 | Completed | Dosimetric Analysis of Vaginal Cuff Brachytherapy in Endometrial Carcinoma | January 2004 | July 2008 | |
| NCT00334295 | Completed | Phase 2 | Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma. | December 2002 | January 2011 |
| NCT00423254 | Completed | Phase 1 | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. | February 2007 | November 2009 |
| NCT00483327 | Completed | Phase 2 | Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate | June 2007 | October 2013 |
| NCT00729586 | Completed | Phase 2 | Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer | September 2008 | February 2017 |
| NCT00756847 | Completed | Phase 1 | Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors | September 2008 | October 2012 |
| NCT00879359 | Completed | Phase 2 | Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer | December 2007 | February 2012 |
| NCT00997373 | Completed | N/A | Letrozole as a Treatment of Endometrial Cancer | October 2009 | September 2013 |
| NCT01455493 | Completed | Phase 2 | A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma | December 2011 | January 2014 |
| NCT02017353 | Completed | Phase 2 | Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma | October 2013 | October 2016 |
| NCT02025985 | Completed | Phase 2 | Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies | April 9, 2014 | March 29, 2017 |
| NCT02465541 | Completed | N/A | Gentle Yoga and Dietary Counseling in Improving Physical Function and Quality of Life in Stage I-II Endometrial Cancer Survivors | July 23, 2013 | April 27, 2022 |
| NCT02506816 | Completed | Preoperative Olaparib Endometrial Carcinoma Study (POLEN) | February 2016 | March 2019 | |
| NCT02630823 | Completed | Phase 1 | MK-3475 Immunotherapy in Endometrial Carcinoma | February 5, 2016 | October 3, 2020 |
| NCT02646319 | Completed | Early Phase 1 | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations | January 2016 | April 24, 2018 |
| NCT03849469 | Completed | Phase 1 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors | May 29, 2019 | February 16, 2023 |
| NCT04474184 | Completed | Phase 1 | Development of a New Early Detection Test to Reduce Racial Disparities in Endometrial Cancer (EC) Death Rates | February 1, 2020 | January 25, 2023 |
| NCT04830332 | Completed | N/A | Correlation of Peritoneal Fluid CA-125 Levels With Postoperative Tumor Histology | December 1, 2011 | December 1, 2012 |
| NCT05894915 | Not yet recruiting | N/A | Study and Transformation of Tumor Molecular Features Screening Model of Endometrial Carcinoma Surgical Approach | June 1, 2023 | December 31, 2025 |
| NCT06102252 | Not yet recruiting | N/A | Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as an Adjuvant Treatment in Endometrial Carcinoma | November 2023 | November 2025 |
| NCT04152499 | Recruiting | Phase 1/Phase 2 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies | February 28, 2020 | December 2025 |
| NCT04159155 | Recruiting | Phase 2/Phase 3 | A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer | November 17, 2020 | September 12, 2027 |
| NCT05714553 | Recruiting | Phase 1/Phase 2 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | March 8, 2023 | January 2025 |
| NCT05950464 | Recruiting | Phase 1 | Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer | December 18, 2023 | April 30, 2026 |
| NCT05139368 | Recruiting | N/A | Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer | November 11, 2021 | November 15, 2027 |
| NCT05316467 | Recruiting | Phase 2/Phase 3 | Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma | May 1, 2022 | February 28, 2026 |
| NCT05669430 | Recruiting | Phase 1 | A Study of GV20-0251 in Patients With Solid Tumor Malignancies | March 23, 2023 | June 15, 2026 |
| NCT05691010 | Recruiting | Early Phase 1 | A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer | January 10, 2023 | January 10, 2025 |
| NCT04224467 | Recruiting | N/A | The Application of Real-Time Near-infrared Imaging in Gynecological Surgery | January 1, 2020 | November 2024 |
| NCT04251416 | Recruiting | Phase 2 | A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma | March 17, 2020 | February 2026 |
| NCT02611024 | Recruiting | Phase 1/Phase 2 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | May 6, 2016 | March 2026 |
| NCT06365905 | Recruiting | Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding | June 1, 2024 | June 30, 2027 | |
| NCT04567771 | Recruiting | N/A | Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer | December 4, 2020 | October 15, 2024 |
| NCT04576104 | Recruiting | Phase 2 | Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer | November 29, 2021 | November 30, 2024 |
| NCT02628067 | Recruiting | Phase 2 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | December 18, 2015 | May 4, 2027 |
| NCT04652076 | Recruiting | Phase 1/Phase 2 | GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab | December 14, 2020 | July 30, 2026 |
| NCT04678414 | Recruiting | Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer | April 1, 2019 | February 2, 2027 | |
| NCT04716686 | Recruiting | Phase 2 | Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma | June 1, 2021 | December 31, 2026 |
| NCT06413992 | Recruiting | Phase 2 | Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer | May 10, 2024 | June 1, 2027 |
| NCT04839614 | Recruiting | N/A | Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia | August 1, 2021 | June 30, 2025 |
| NCT04851119 | Recruiting | Phase 1/Phase 2 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | November 8, 2021 | June 30, 2028 |
| NCT05036681 | Recruiting | Phase 2 | A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma | September 30, 2021 | December 11, 2024 |
| NCT05059444 | Recruiting | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | September 7, 2021 | February 2028 | |
| NCT05086692 | Recruiting | Phase 1/Phase 2 | A Beta-only IL-2 ImmunoTherapY Study | August 27, 2021 | December 30, 2026 |
| NCT04080284 | Recruiting | Phase 2 | Trial of Maintenance With Niraparib- Uterine Serous Carcinoma | December 30, 2019 | July 1, 2026 |
| NCT03945786 | Suspended | Diagnostic Performance of Hybrid PET/MRI in the Staging of Endometrial Carcinoma | June 3, 2019 | December 31, 2022 | |
| NCT06253494 | Suspended | Phase 1/Phase 2 | Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer | May 14, 2024 | December 31, 2028 |
| NCT04178460 | Terminated | Phase 1 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment | February 3, 2020 | March 2, 2022 |
| NCT01184053 | Terminated | Phase 2 | Trisenox® in Women With Metastatic Endometrial Cancer | March 2010 | March 2012 |
| NCT03877627 | Unknown status | N/A | The Clinical Significance of Sentinel Lymph Node Imaging Combined With Imaging Examination in Pelvic and Peritoneal Lymphadenectomy for Endometrial Carcinoma | April 1, 2022 | April 1, 2023 |
| NCT02368067 | Unknown status | N/A | Improved Method of Detecting Cancer Metastases | June 2014 | December 2015 |
| NCT01273636 | Unknown status | Risk Factors for Concurrent Endometrial Carcinoma in Patients With a Curettage Diagnosis of Endometrial Hyperplasia | January 2005 | June 2011 | |
| NCT05121363 | Unknown status | Phase 2 | A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma | December 2021 | July 2023 |
| NCT03076372 | Unknown status | Phase 1 | A Study Evaluating MM-310 in Patients With Solid Tumors | February 22, 2017 | December 2018 |
| NCT05712941 | Withdrawn | Phase 3 | Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer | April 18, 2023 | March 2025 |
| NCT03902379 | Withdrawn | N/A | Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer | July 27, 2016 | May 31, 2020 |
- Disase is a (Disease Ontology)
- DOID:1380
- Cross Reference ID (Disease Ontology)
- MESH:D016889
- Cross Reference ID (Disease Ontology)
- MESH:D018269
- Cross Reference ID (Disease Ontology)
- NCI:C7558
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:30289006
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:93781006
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0206687
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0476089
- Exact Synonym (Disease Ontology)
- carcinoma of the Endometrium
- Exact Synonym (Disease Ontology)
- endometrioid carcinoma
- Exact Synonym (Disease Ontology)
- endometrioid carcinoma of female Reproductive system
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0012114